View source for Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma

{{item
|type_parameter=research
|description_parameter=Hodgkin Lymphoma (HL) is a rare malignancy, with 500 new cases annually in young Australians. While 70 per cent of patients are cured with front line treatment, 30 per cent of patients require second line therapy which often fails resulting in death. Immunotherapy and targeted therapies have dramatically improved survival in haematological malignancies. This study will combine two agents currently approved in recurrent HL to maximise survival of these young Australians.
|aim_parameter={{aim parameter|maximise survival of these young Australians}}
|state_parameter=ongoing
|start_date_parameter=2021-01-01
|end_date_parameter=2026-01-01
|location_parameter=Australia
|location_link=No
|URL_parameter=https://www.grants.gov.au/Ga/Show/9d10d108-a60a-443f-90b2-e834774a542b
|author_parameter={{author parameter
|aut_nam=Portia Dilena
|aut_url=https://scholars.latrobe.edu.au/pdilena
|aut_con=non contact
}}
|contributor_parameter={{contributor parameter
|con_typ=individual
|con_nam=Eliza Hawkes
|con_tas=Lead Chief Investigator
|con_cop=paid
|con_dates=No
}}
|input_parameter={{input parameter
|inp_typ=funding
|inp_inp=1,225,487.40
|inp_currency=AUD
|inp_url=https://www.grants.gov.au/Ga/Show/9d10d108-a60a-443f-90b2-e834774a542b
}}
}}